Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback